WASHINGTON: A new generation of obesity drugs often delivers dramatic weight loss, but many patients wonder what happens when they stop treatment.
One study published on Monday in the Journal of the American Medical Association provides an answer: much of the weight comes back, signaling patients may be locked into long term dependence on the drugs.
The research was based on weekly injections of tirzepatide, the compound in Eli Lilly´s new weight loss drug Zepbound that was approved by the United States last month. After 36 weeks, 670 adults achieved a notable mean weight loss of 20.9 percent.
The group was then split into two, with half continuing on Zepbound, and the other half given a placebo. At 88 weeks, those on the placebo regained almost half of the weight they had lost, ending up 9.9 percent lower than their baseline.
Those on Zepbound continued to lose weight, ending 25.3 percent lower than where they had started. The trial patients were mostly women and had a mean age of 48, with a mean weight at the outset was 107.3 kilograms (236.6 pounds). All participants were encouraged to consume 500 calories less each day than they burnt and take at least 150 minutes of exercise per week.
Common side effects were gastrointestinal issues including nausea, diarrhea, constipation and vomiting, said the study. Study authors, led by Louis Aronne at Weill Cornell Medicine, New York, said the results “emphasize the need to continue pharmacotherapy to prevent weight regain and ensure the maintenance of weight reduction.”
They added the latest research adds to four previous trials that showed “medications, including potent antiobesity medications such as semaglutide, have demonstrated that weight is substantially regained” after stopping treatment.
Semaglutide is the active ingredient in Novo Nordisk´s Ozempic and Wegovy, which, like Zepbound, are examples of so-called “GLP-1 agonists” that work by mimicking the function of a hormone that secretes insulin, slows down the emptying of the stomach, and suppresses appetite.
The Mohajer 6 drone is displayed during Iran's defence industry achievements exhibition, on August 23, 2023 in...
Sadhvi Ritambhara arrives ahead of the consecration ceremony of Ram Mandir in Ayodhya, India, on January 20, 2024....
This photo illustration shows the DeepSeek app on a mobile phone in Beijing on January 27, 2025. — AFPSAN FRANCISCO:...
India's Home Minister Amit Shah at the National Centre for the Performing Arts in Mumbai on Oct 10, 2024. —...
The image shows a glimpse from the life of poor Afghans. — AFP/ScreenshotISLAMABAD: The head of the World Food...
This aerial view shows the P4 laboratory on the campus of the Wuhan Institute of Virology in Wuhan in China’s...